aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Rheos Medicines is a biopharmaceutical company focused on innovating therapies by modulating metabolic pathways in immune cells to treat diseases. The firm develops novel medicines and discovers new therapies, serving clients primarily in Massachusetts.
Rheos Medicines has made significant strides in the biopharmaceutical field, contributing to the development of advanced treatments for immune-related conditions. Their work has garnered attention for its potential impact on healthcare and disease management.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Therapeutics, Medicines
Technology
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, HealthTech
Geographic Exposure
United States
When was Rheos Medicines founded?
Rheos Medicines was founded in 2018.
Where is Rheos Medicines’s headquarters located?
Rheos Medicines’s headquarters is located in Cambridge, MA, US.
When was Rheos Medicines’s last funding round?
Rheos Medicines’s most recent funding round was for $60M (USD) in March 2018.
How many employees does Rheos Medicines have?
Rheos Medicines has 33 employees as of Feb 5, 2024.
How much has Rheos Medicines raised to-date?
As of July 05, 2023, Rheos Medicines has raised a total of $60M (USD) since Mar 22, 2018.
Add Comparison
Total Raised to Date
$60M
USD
Last Update Mar 22, 2018
Last Deal Details
$60M
USD
Mar 22, 2018
Series A
Total Employees Over Time
33
As of Feb 2024
Rheos Medicines Address
38 Sidney St
Cambridge,
Massachusetts
02139
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts